Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy

Dawn Owen, Charles S. Mayo, Limin Song, Kamran Ahmed, Nadia N Laack, Kenneth Olivier

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Spine stereotactic body radiation therapy (SBRT) is becoming widely accepted as first-line treatment of oligometastatic spine disease as well as in the postoperative setting. The reported incidence of myelopathy is very low and guidelines vary widely on the maximum tolerable dose of the spinal cord and thecal sac. Methods and materials Between April 2008 and December 2010, radiation parameters were exported for 46 patients treated with spine SBRT at the Mayo Clinic. Using an in-house data mining program, dose-volume histogram constraints were extracted, including dose prescription, dose fractionation, planning target volume, planning target volume coverage, maximum dose to the cord, D2cc thecal sac, and D2cc spinal cord. Diagnostic magnetic resonance imaging scans and/or computed tomography myelograms were fused with the planning set to delineate the cord and thecal sac for receiver operating characteristic analysis of cord and thecal sac subvolume doses. A high-resolution planning at-risk volume was created in 1-mm increments for cord (1-7 mm) and the thecal sac (1-2 mm) to examine dose gradients that might be correlated with toxicity. Results No patients experienced myelopathy with a median follow-up of 14 months. The most common toxicities were pain and nausea. Median values of D2cc maximum dose (maximum dose received by 2 cc of the organ at risk; biologically equivalent 2-Gy dose maximum [EQD2]) for cord and thecal sac were 38.5 Gy (range, 7.5-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy), respectively. Median values for high-dose subvolumes for cord and thecal sac were 2 times higher than the doses for 5% predicted grade 3 cord toxicity as recommended in the current literature. Cord D0.1cc[EQD2] ≥23.8 Gy was correlated with pain flare (n = 5). Thecal sac D2cc [EQD2] ≥29.3 Gy was a significant indicator of nausea. Conclusion Current guidelines may overestimate the risk of myelopathy from spine SBRT. The current study's population included both radiation-naïve and retreatment cases, but no myelopathy was observed despite exceeding recommended spine limits.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalAdvances in Radiation Oncology
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Organs at Risk
Spinal Cord Diseases
Spine
Radiotherapy
Nausea
Spinal Cord
Guidelines
Radiation
Dose Fractionation
Pain
Retreatment
Data Mining
ROC Curve
Prescriptions
Tomography
Magnetic Resonance Imaging
Incidence
Population

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy. / Owen, Dawn; Mayo, Charles S.; Song, Limin; Ahmed, Kamran; Laack, Nadia N; Olivier, Kenneth.

In: Advances in Radiation Oncology, Vol. 1, No. 1, 01.01.2016, p. 76-81.

Research output: Contribution to journalArticle

Owen, Dawn ; Mayo, Charles S. ; Song, Limin ; Ahmed, Kamran ; Laack, Nadia N ; Olivier, Kenneth. / Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy. In: Advances in Radiation Oncology. 2016 ; Vol. 1, No. 1. pp. 76-81.
@article{a95f0d062bf946819862e6085a9b181f,
title = "Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy",
abstract = "Background Spine stereotactic body radiation therapy (SBRT) is becoming widely accepted as first-line treatment of oligometastatic spine disease as well as in the postoperative setting. The reported incidence of myelopathy is very low and guidelines vary widely on the maximum tolerable dose of the spinal cord and thecal sac. Methods and materials Between April 2008 and December 2010, radiation parameters were exported for 46 patients treated with spine SBRT at the Mayo Clinic. Using an in-house data mining program, dose-volume histogram constraints were extracted, including dose prescription, dose fractionation, planning target volume, planning target volume coverage, maximum dose to the cord, D2cc thecal sac, and D2cc spinal cord. Diagnostic magnetic resonance imaging scans and/or computed tomography myelograms were fused with the planning set to delineate the cord and thecal sac for receiver operating characteristic analysis of cord and thecal sac subvolume doses. A high-resolution planning at-risk volume was created in 1-mm increments for cord (1-7 mm) and the thecal sac (1-2 mm) to examine dose gradients that might be correlated with toxicity. Results No patients experienced myelopathy with a median follow-up of 14 months. The most common toxicities were pain and nausea. Median values of D2cc maximum dose (maximum dose received by 2 cc of the organ at risk; biologically equivalent 2-Gy dose maximum [EQD2]) for cord and thecal sac were 38.5 Gy (range, 7.5-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy), respectively. Median values for high-dose subvolumes for cord and thecal sac were 2 times higher than the doses for 5{\%} predicted grade 3 cord toxicity as recommended in the current literature. Cord D0.1cc[EQD2] ≥23.8 Gy was correlated with pain flare (n = 5). Thecal sac D2cc [EQD2] ≥29.3 Gy was a significant indicator of nausea. Conclusion Current guidelines may overestimate the risk of myelopathy from spine SBRT. The current study's population included both radiation-na{\"i}ve and retreatment cases, but no myelopathy was observed despite exceeding recommended spine limits.",
author = "Dawn Owen and Mayo, {Charles S.} and Limin Song and Kamran Ahmed and Laack, {Nadia N} and Kenneth Olivier",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.adro.2015.12.001",
language = "English (US)",
volume = "1",
pages = "76--81",
journal = "Advances in Radiation Oncology",
issn = "2452-1094",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy

AU - Owen, Dawn

AU - Mayo, Charles S.

AU - Song, Limin

AU - Ahmed, Kamran

AU - Laack, Nadia N

AU - Olivier, Kenneth

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Spine stereotactic body radiation therapy (SBRT) is becoming widely accepted as first-line treatment of oligometastatic spine disease as well as in the postoperative setting. The reported incidence of myelopathy is very low and guidelines vary widely on the maximum tolerable dose of the spinal cord and thecal sac. Methods and materials Between April 2008 and December 2010, radiation parameters were exported for 46 patients treated with spine SBRT at the Mayo Clinic. Using an in-house data mining program, dose-volume histogram constraints were extracted, including dose prescription, dose fractionation, planning target volume, planning target volume coverage, maximum dose to the cord, D2cc thecal sac, and D2cc spinal cord. Diagnostic magnetic resonance imaging scans and/or computed tomography myelograms were fused with the planning set to delineate the cord and thecal sac for receiver operating characteristic analysis of cord and thecal sac subvolume doses. A high-resolution planning at-risk volume was created in 1-mm increments for cord (1-7 mm) and the thecal sac (1-2 mm) to examine dose gradients that might be correlated with toxicity. Results No patients experienced myelopathy with a median follow-up of 14 months. The most common toxicities were pain and nausea. Median values of D2cc maximum dose (maximum dose received by 2 cc of the organ at risk; biologically equivalent 2-Gy dose maximum [EQD2]) for cord and thecal sac were 38.5 Gy (range, 7.5-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy), respectively. Median values for high-dose subvolumes for cord and thecal sac were 2 times higher than the doses for 5% predicted grade 3 cord toxicity as recommended in the current literature. Cord D0.1cc[EQD2] ≥23.8 Gy was correlated with pain flare (n = 5). Thecal sac D2cc [EQD2] ≥29.3 Gy was a significant indicator of nausea. Conclusion Current guidelines may overestimate the risk of myelopathy from spine SBRT. The current study's population included both radiation-naïve and retreatment cases, but no myelopathy was observed despite exceeding recommended spine limits.

AB - Background Spine stereotactic body radiation therapy (SBRT) is becoming widely accepted as first-line treatment of oligometastatic spine disease as well as in the postoperative setting. The reported incidence of myelopathy is very low and guidelines vary widely on the maximum tolerable dose of the spinal cord and thecal sac. Methods and materials Between April 2008 and December 2010, radiation parameters were exported for 46 patients treated with spine SBRT at the Mayo Clinic. Using an in-house data mining program, dose-volume histogram constraints were extracted, including dose prescription, dose fractionation, planning target volume, planning target volume coverage, maximum dose to the cord, D2cc thecal sac, and D2cc spinal cord. Diagnostic magnetic resonance imaging scans and/or computed tomography myelograms were fused with the planning set to delineate the cord and thecal sac for receiver operating characteristic analysis of cord and thecal sac subvolume doses. A high-resolution planning at-risk volume was created in 1-mm increments for cord (1-7 mm) and the thecal sac (1-2 mm) to examine dose gradients that might be correlated with toxicity. Results No patients experienced myelopathy with a median follow-up of 14 months. The most common toxicities were pain and nausea. Median values of D2cc maximum dose (maximum dose received by 2 cc of the organ at risk; biologically equivalent 2-Gy dose maximum [EQD2]) for cord and thecal sac were 38.5 Gy (range, 7.5-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy), respectively. Median values for high-dose subvolumes for cord and thecal sac were 2 times higher than the doses for 5% predicted grade 3 cord toxicity as recommended in the current literature. Cord D0.1cc[EQD2] ≥23.8 Gy was correlated with pain flare (n = 5). Thecal sac D2cc [EQD2] ≥29.3 Gy was a significant indicator of nausea. Conclusion Current guidelines may overestimate the risk of myelopathy from spine SBRT. The current study's population included both radiation-naïve and retreatment cases, but no myelopathy was observed despite exceeding recommended spine limits.

UR - http://www.scopus.com/inward/record.url?scp=84995494472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995494472&partnerID=8YFLogxK

U2 - 10.1016/j.adro.2015.12.001

DO - 10.1016/j.adro.2015.12.001

M3 - Article

AN - SCOPUS:84995494472

VL - 1

SP - 76

EP - 81

JO - Advances in Radiation Oncology

JF - Advances in Radiation Oncology

SN - 2452-1094

IS - 1

ER -